// App-Quantinova.ai

518 : Palbociclib combined with endocrine treatment in breast cancer patients with high relapse risk after neoadjuvant chemotherapy: Subgroup analyses of premenopausal patients in PENELOPE-B.

Researchers

Presenter

  • Frederik Marm

Principal Investigators

  • Michael Untch

  • Herve R. Bonnefoi

  • Sung-Bae Kim

  • Harry Douglas Bear

  • Nicole Mc Carthy

  • Karen A. Gelmon

  • Jos A. Garca-Senz

  • Catherine Margaret Kelly

  • Toralf Reimer

  • Masakazu Toi

  • Hope S. Rugo

  • Michael Gnant

  • Andreas Makris

  • Mariajose Lechuga

  • Sabine Seiler

  • Fenja Seither

  • Sibylle Loibl

Medical Centers

  • Medical Faculty Mannheim, Heidelberg University, University Hospital Mannheim, Mannheim, Germany

  • Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Universidad Complutense de Madrid, GEICAM Breast Cancer Group, Madrid, Spain

  • HELIOS Klinikum Berlin-Buch, Berlin, Germany

  • Institut Bergonié and Université de Bordeaux INSERM U916, Bordeaux, France

  • Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

  • Division of Surgical Oncology, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA

  • Breast Cancer Trials Australia and New Zealand and University of Queensland, Brisbane, Australia

  • Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada

  • Service de Oncología Médica, Hospital Clínico San Carlos, Madrid, Spain

  • Breast Group, Cancer Trials Ireland

  • Dublin, Ireland

  • Department of Obstetrics and Gynecology, University of Rostock, Rostock, Germany

  • Department of Gastroenterology, Graduate School of Medicine Kobe University, Kobe, Japan

  • University of California, San Francisco, San Francisco, CA

  • Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria

  • Mount Vernon Cancer Centre, Northwood, United Kingdom

  • Pfizer Inc, San Diego, CA

  • German Breast Group (GBG), Neu-Isenbug, Germany

Locations

  • Germany

  • Spain

  • France

  • Australia

  • Canada

  • Ireland

  • Japan

  • Austria

  • United Kingdom

Companies

  • Pfizer Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Stromal interaction molecule 1

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Palbociclib

  • Tamoxifen

  • taxane

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • NCT01864746

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved